Nasdaq · Healthcare

C4 Therapeutics, Inc. (CCCC)

As-reported financials and recent SEC filings for C4 Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$35.9M

Net income

$-105.0M

Net margin

—

Diluted EPS

$-1.27

ROE

-40.9%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$35.9M	$35.6M	$20.8M	$31.1M	$45.8M
Gross profit	—	—	—	—	—
Operating income	$-115.2M	$-119.6M	$-139.0M	$-129.5M	$-82.1M
Net income	$-105.0M	$-105.3M	$-132.5M	$-128.2M	$-83.9M
Diluted EPS	$-1.27	$-1.52	$-2.67	$-2.62	$-1.82

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-07-02

42026-07-02

42026-06-26

42026-06-26

42026-06-26

42026-06-26

42026-06-26

42026-06-26

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on CCCC

Search C4 Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.